Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.

Author: Benzinga Newsdesk | October 16, 2025 07:47am

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North American Menopause Society (NAMS) 2025 Annual Meeting, taking place October 21–25, 2025, in Orlando, Florida. This will mark Entera's first presentation at NAMS.

The presentation will showcase new Phase 2 data from EB613 in early postmenopausal women with low bone mass or osteoporosis, examining bone mineral density outcomes over six months. By focusing on this population - a stage where women are at rising risk but few receive anabolic therapy - this analysis will examine the potential role of EB613 earlier in the treatment journey, where injectable options remain underutilized.

"Anabolic therapies remain significantly underutilized despite their proven ability to rebuild bone, largely because they are only available as injections," said Miranda Toledano, Chief Executive Officer of Entera. "By delivering the first oral anabolic tablet, EB613 has the potential to move treatment earlier in the care continuum and broaden access for the over 200 million women worldwide living with osteoporosis. At NAMS, we will present new data examining the timing of intervention in postmenopausal women - an important clinical and market question."

Posted In: ENTX